
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Tufts Center for the Study of Drug Development recently completed a study, which was released September 12. The findings show that even though the rate at which investigational drugs received marketing approval in the U.S. has declined in recent years, the cardiovascular approval rate trailed other drug approvals, while the time needed to develop cardiovascular drugs rose.
Read the full release






